z-logo
Premium
Immortal phenotype of the HeLa variant D98 is recessive in hybrids formed with normal human fibroblasts
Author(s) -
PereiraSmith Olivia M.,
Stein Gretchen H.,
Robetorye Susan,
MeyerDemarest Sarah
Publication year - 1990
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.1041430204
Subject(s) - hela , phenotype , cell fusion , biology , population , genetics , gene , ploidy , cell division , cell , mechanism (biology) , cell culture , microbiology and biotechnology , medicine , philosophy , environmental health , epistemology
Normal human cells such as human diploid fibroblasts (HDF) have a finite pro‐liferative lifespan in culture. Previous studies have shown that the limited lifespan phenotype is dominant in cell hybrids formed by fusion of HDF to at least 23 different kinds of immortal human cells. However, two independent studies reported that hybrid clones formed by the fusion of HDF to the HeLa variant D98 had unlimited division potential. Those results were potentially very important because they implied that a) there is a dominant mechanism for immortalization of human cells in addition to the well‐documented recessive mechanism, and b) a dominant mechanism would lend itself to identification of the immortalizing gene. Consequently, we carried out more detailed studies of the behavior of D98 cells in hybrids. Our results indicate that the majority of D98 x HDF hybrid clones exhibit a clear‐cut finite proliferative lifespan phenotype. In addition, these hybrid cell populations often give rise to an immortal focus of cells that can be seen to take over the population of mortal cells at the end of their lifespan. This phenomenon reconciles our data with the previous reports of immortal D98 x HDF hybrid clones and leads us to conclude that D98 cells do not express a dominant immortalizing gene.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here